RJA
ADAP
Raymond James & Associates’s Adaptimmune Therapeutics ADAP Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-10,218
| Closed | -$9.96K | – | 3940 |
|
|
2024
Q2 | $9.96K | Buy |
+10,218
| New | +$9.96K | ﹤0.01% | 3883 |
|
|
2024
Q1 | – | Sell |
-10,218
| Closed | -$8.1K | – | 3869 |
|
|
2023
Q4 | $8.1K | Sell |
10,218
-151
| -1% | -$120 | ﹤0.01% | 3754 |
|
|
2023
Q3 | $8.09K | Sell |
10,369
-80
| -0.8% | -$62 | ﹤0.01% | 3731 |
|
|
2023
Q2 | $9.67K | Sell |
10,449
-849
| -8% | -$785 | ﹤0.01% | 3751 |
|
|
2023
Q1 | $12.3K | Buy |
11,298
+1,250
| +12% | +$1.36K | ﹤0.01% | 3777 |
|
|
2022
Q4 | $14.7K | Sell |
10,048
-525
| -5% | -$766 | ﹤0.01% | 3739 |
|
|
2022
Q3 | $11K | Hold |
10,573
| – | – | ﹤0.01% | 3765 |
|
|
2022
Q2 | $18K | Hold |
10,573
| – | – | ﹤0.01% | 3791 |
|
|
2022
Q1 | $22K | Buy |
+10,573
| New | +$22K | ﹤0.01% | 3879 |
|
|
2020
Q3 | – | Sell |
-10,401
| Closed | -$104K | – | 3463 |
|
|
2020
Q2 | $104K | Sell |
10,401
-10,400
| -50% | -$104K | ﹤0.01% | 3244 |
|
|
2020
Q1 | $57K | Sell |
20,801
-8,610
| -29% | -$23.6K | ﹤0.01% | 3269 |
|
|
2019
Q4 | $35K | Buy |
29,411
+3,546
| +14% | +$4.22K | ﹤0.01% | 3505 |
|
|
2019
Q3 | $39K | Buy |
25,865
+3,730
| +17% | +$5.62K | ﹤0.01% | 3438 |
|
|
2019
Q2 | $89K | Sell |
22,135
-8,050
| -27% | -$32.4K | ﹤0.01% | 3386 |
|
|
2019
Q1 | $130K | Buy |
30,185
+7,279
| +32% | +$31.3K | ﹤0.01% | 3309 |
|
|
2018
Q4 | $132K | Buy |
22,906
+8,498
| +59% | +$49K | ﹤0.01% | 3235 |
|
|
2018
Q3 | $195K | Sell |
14,408
-1,188
| -8% | -$16.1K | ﹤0.01% | 3274 |
|
|
2018
Q2 | $185K | Sell |
15,596
-9,544
| -38% | -$113K | ﹤0.01% | 3261 |
|
|
2018
Q1 | $282K | Buy |
25,140
+8,056
| +47% | +$90.4K | ﹤0.01% | 2906 |
|
|
2017
Q4 | $114K | Buy |
+17,084
| New | +$114K | ﹤0.01% | 3151 |
|